Clinical Trials
3 trialsNCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03514121 2024-11-22
FPA150-001
Five Prime Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT03694834 2023-11-28
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated